Abeona Therapeutics (ABEO) news
Recent news
Abeona Therapeutics, Inc.: Oppenheimer cuts target price to $21 from $22
Oppenheimer & Co. has revised its price target for Abeona Therapeutics, Inc. (NASDAQ:ABEO) to $21 from $22, while maintaining its Outperform rating for the stock. The adjustment follows the firm’s updated analysis of the company’s recent developments, including progress in commercial launch of…
AInvest Wire · Aug 14, 2026Abeona Therapeutics 2Q loss/share 0.35c
Abeona Therapeutics Inc. (Nasdaq: ABEO) reported a net loss of $0.35 per share for the second quarter of 2026, reflecting continued financial challenges as the company transitions from a clinical-stage to a commercial-stage biopharmaceutical entity. The loss, while narrower than previous periods,…
AInvest Wire · Aug 13, 2026Abeona Therapeutics still targets 2027 for ABO-701 IND submission
Abeona Therapeutics Inc. (Nasdaq: ABEO) continues to target the second half of 2027 for the submission of an Investigational New Drug (IND) application for its lead development candidate, ABO-701, a novel engineered T-cell therapy targeting Prostate-Specific Membrane Antigen (PSMA) in advanced…
AInvest Wire · Jun 4, 2026Abeona Therapeutics: FDA pre-IND meeting for ABO-701 was constructive
Abeona Therapeutics Inc. (Nasdaq: ABEO) has reported progress in its development pipeline for ABO-701, a novel engineered T-cell therapy targeting Prostate-Specific Membrane Antigen (PSMA) in advanced prostate cancer. The company recently held a pre-Investigational New Drug (IND) meeting with the…
AInvest Wire · Jun 4, 2026Abeona Therapeutics - targets IND submission for ABO-701 in 2027 - SEC filing
Abeona Therapeutics Inc. (Nasdaq: ABEO) has outlined plans to submit an Investigational New Drug (IND) application for its lead asset, ABO-701, in the second half of 2027, as disclosed in its recent SEC filings and press releases . ABO-701 is an autologous engineered T-cell therapy targeting…
AInvest Wire · Jun 4, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.